Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib helps regrow hair in teens with severe alopecia areata.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This randomized controlled trial found that topical clobetasol propionate 0.05% ointment is significantly more effective than topical tacrolimus 0.1% ointment in promoting hair regrowth in patients with alopecia areata, with effective results observed in 79.31% of clobetasol users compared to 44.82% of tacrolimus users.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This review discusses the efficacy and safety of intralesional triamcinolone acetonide for treating acne keloidalis nuchae, highlighting its significant effectiveness with rare side effects when used properly.

This study introduced the C-CAT, a new assessment tool for central centrifugal cicatricial alopecia, and found that established treatments improved symptoms in most patients over six months.

This study found that group behavior therapy for trichotillomania led to greater short-term symptom improvement compared to supportive therapy, but did not achieve clinically significant changes or prevent relapse over six months.

This article reviews the use of deoxycholic acid as a nonsurgical treatment for unwanted fat in the cosmetic field but reports no new clinical results.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This study found that combining high-density fat grafting with botulinum toxin A significantly improved symptoms of Raynaud’s phenomenon, including reducing pain and cold sensitivity, speeding up ulcer healing, and enhancing blood perfusion, compared to fat grafting alone.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

In a mouse model of peripheral vascular disease, this study found that recombinant thymosin β4 treatment increased expression levels of certain proteins, promoting angiogenesis.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This study found that betulinic acid inhibits hepatitis C virus replication by suppressing the NF-κB- and ERK1/2-mediated COX-2 pathway, suggesting its potential as a therapeutic supplement.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This case report documents a rare instance of triangular temporal alopecia in an adult woman, emphasizing the importance of correct diagnosis to avoid unnecessary treatments, and reviews the literature on TTA.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.